Biotech Sector Faces Workforce Cuts Amid FDA Approvals
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
- Latest
- Trending
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Nanox Imaging reports fourth-quarter 2023 earnings with progress in the utilization of ARC systems, scanning patients. CEO suggests varying connection ...
The stock has dropped 29% in the last year, hitting a low of $11.25 on Oct. 27. A study shows ...
Medical technology company TransMedics Group, Inc. is set to release its Q4 and full year 2023 financial results, highlighting its ...
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.